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Absence of Classical MAP Kinase Pathway Signalling
in Merkel Cell Carcinoma
Roland Houben1, Barbara Michel1, Claudia S. Vetter-Kauczok1, Claudia Pfo¨hler2, Barbara Laetsch3,
Manfred D. Wolter4, J. Helen Leonard5, Uwe Trefzer6, Selma Ugurel7, David Schrama1 and
Juergen C. Becker1
Merkel cell carcinoma (MCC) is a highly metastatic skin tumor. To assess the relevance of the Ras/Raf/MEK/MAP
kinase pathway, we analyzed for activating B-Raf mutations and we elucidated the presence of the Raf Kinase
Inhibitor Protein (RKIP) and extracellular signal-regulated kinase (ERK) as well as the phosphorylation status of
ERK. All MCC samples were negative for the B-RafV600E mutation. Remarkably, RKIP, which was shown to
interfere with the activation of MEK by Raf, was highly expressed in primary as well as in metastatic MCC.
Immunohistochemical analysis of the phosphorylation status of ERK revealed in 42 out of 44 samples a complete
lack of activated ERK in the tumor cells although ERK is expressed; in the two positive cases phosphorylated ERK
was restricted to a minor fraction of the tumor cells. Western blot analysis of three MCC-derived cell lines
revealed in one case the pattern present in situ (i.e. high RKIP expression and complete absence of
phosphorylated ERK). In summary, our data demonstrate the inactivity of the classical MAP kinase signal
transduction pathway in MCC, which seems to be because of lack of activation as well as active deactivation.
These findings should be accounted for in future therapeutic approaches for this tumor.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare form of skin cancer of
neuroendocrine origin that has been described as a very
aggressive cutaneous malignancy (Poulsen, 2004). Frequently
discussed is the relationship to intraepidermal Merkel cells
(Goessling et al., 2002). The tumor itself mostly appears
dermal, very rarely intraepidermal with a pagetoid pattern.
The estimated incidence in the Caucasian population of the
United States of America is 0.23 per 100,000 people. Only
5% of the MCC cases occur before the age of 50 years and the
tumors are commonly located in body areas that are exposed
to the sun (Miller and Rabkin, 1999). Notably, the genetic
and molecular mechanisms involved in the development and
progression of MCC are not well defined.
The Ras/Raf/MEK/ERK intracellular signalling cascade is a
major determinant in the control of cell growth, differentia-
tion, and survival and can be activated in response to a
variety of extracellular stimuli (Naumann et al., 1997).
Stimulation of growth factor receptors results in the activation
of the small G-protein Ras, which in turn interacts with the
protein kinase Raf leading to its activation. MAP kinase
kinase kinase (Raf) phosphorylates and activates MAP kinase
kinase (MEK), and MEK phosphorylates and activates extra-
cellular signal-regulated kinase (ERK) 1/2 (p42/p44 MAP
kinases) (Figure 1). Although Raf and MEK appear largely
restricted to only one class of substrates, ERK targets more
than 70 substrates including membrane, cytoskeletal, cyto-
plasmic, nuclear, and even mitochondrial proteins (Lewis
et al., 1998; Chen et al., 2001). Recently, a negative regulator
of this pathway has been described (Yeung et al., 1999). The
Raf Kinase Inhibitor Protein (RKIP) binds to either Raf or MEK
and thereby interferes with the activation of MEK by Raf
(Yeung et al., 2000) (Figure 1).
The importance of the Ras/Raf/MEK/ERK signalling path-
way for carcinogenesis is well established. Indeed, Ras genes
(K-ras, H-ras, and N-ras) are the most frequently mutated
oncogenes detected in human cancer (Bos, 1989; Ellis and
Clark, 2000). In addition, B-Raf mutations were recently
described for a series of human tumors, such as melanoma,
colorectal, ovarian (Davies et al., 2002), thyroid (Cohen
et al., 2003; Kimura et al., 2003), and lung cancer (Brose
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et al., 2002; Naoki et al., 2002). The recent report that the
diminished expression of RKIP, one of the major inhibitors of
the mitogen-activated protein (MAP) kinase pathway, is
associated with tumor progression, that is, metastasis (Fu
et al., 2003), further emphasizes the importance of this
pathway in the oncogenic process.
In contrast to other skin tumors, only a few studies to date
addressed the role of the Ras/Raf/MEK/ERK pathway in the
development of MCC. In this regard, no activating mutations
in any of the Ras genes could be detected in six analyzed
MCC cell lines (Popp et al., 2002a). In fact, only an over-
representation of a polymorphism in codon 27 of H-Ras,
which does not alter the amino-acid sequence, was present.
MCC poses a considerable therapeutic challenge as
frequently neither chemotherapeutic strategies nor radiation
therapy yield satisfactory results (Goessling et al., 2002;
Poulsen, 2004). Therefore, an understanding of the molecular
mechanisms underlying this disease may allow the develop-
ment of more efficient therapies. Consequently, in a
concerted effort we analyzed the Ras/Raf/MEK/ERK pathway
in a set of 49 individual samples of this rare tumor. Specimens
from 22 MCC primary tumors and 27 metastatic lesions were
screened for the presence of the B-RafV600E mutation by a
newly developed real-time PCR assay. In addition, tissue
sections of these MCCs were analyzed immunohistochemi-
cally for the expression of the negative regulator of MAP
kinase signalling, RKIP, as well as for the presence of
activated (phosphorylated) ERK, the critical end point of this
signalling cascade.
RESULTS AND DISCUSSION
Rapid and sensitive scanning for B-RafV600E mutations by
a real-time PCR assay
Ninety-two percent of the B-Raf mutations found in
melanoma are based on the V600E (T1799A) exchange
(Davies et al., 2002). Accordingly, an accurate and quick
assay to analyze DNA for the presence of this mutation
should facilitate the screening of clinical samples. We
therefore, established a simple real-time PCR assay based
on the comparison of PCR reactions with wt or T1799A-
specific primers. When genomic DNA from a melanoma cell
line, which is heterozygous for B-RafV600E, was used as
template, amplification efficiency was nearly identical for
either set of primers (Figure 2a). In contrast, amplification
from genomic DNA of a B-Raf600wt cell line led to a
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Figure 1. The Ras/Raf/MEK/ERK pathway. The small G-protein Ras is active
in the GTP-bound form, whereas th activation of the protein kinases Raf, MEK,
and ERK involves phosphorylation. The proteins (Raf, RKIP, ERK) that were
analyzed in this study are given in bold (GF: growth factor; GFR: growth factor
receptor).
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Figure 2. Real-time PCR assay for the detection of BRafV600E. (a–c) PCR amplification efficacy for the wt and the V600E (T1799A) specific primer sets using
SybrGreen technology. The genomic DNA of (a) the melanoma cell line FM55M2 (heterozygous for BRafV600E), and (c) the melanoma cell line FM3
(homozygously BRaf600wt) served as templates. (b) A 15/1 mixture of both DNAs (equivalent to 30/1 wt/mut allele). (d) Correlation between the logarithmic
wt/mut ratio and DCT.
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significant DCT (Figure 2b). Validation of this assay was
performed by analyzing various mixtures of B-Raf600wt and
B-RafV600E genomic DNA, which demonstrated a tight correla-
tion (coefficient of correlation¼0.98) between the logarith-
mic wt/mut ratio and the DCT value of the real-time PCR
reactions using the wt and T1799A-specific primers (Figure
2c and d). Despite substantial variations of DCT at wt/mut
ratios greater than 100, it was reproducibly possible to detect
the mutated allele even if the wt DNA was spiked with only
3% of the mutated allele (Figure 2d). In contrast, the detection
level by conventional amplification and direct sequencing of
the PCR product was approximately 25% (data not shown).
Therefore, in addition to high speed and low costs, a major
advantage of this real-time PCR-based assay is its high
sensitivity. Indeed, this assay allows detection of the V600E
mutation even when extensive amounts of normal tissue are
present in the sample or when the mutation is not present in
all cancer cells because of heterogeneity of the tumor.
Moreover, the assay allows a semiquantitative estimation of
the frequency of the B-RafV600E mutation in the analyzed
sample. In contrast to sequencing, however, this V600E-
specific PCR will not detect any of the other rare B-Raf
mutations.
To further validate this assay, in particular on genomic
DNA isolated from formalin-fixed and paraffin-embedded
tissues, we analyzed 19 melanoma samples with known
genotype (Houben et al., 2004). To this end, the calculated
wt/mut ratio for those samples that had been demonstrated by
sequencing to be V600E positive ranged between 1 and 8,
whereas the ratio ranged from 468 to 4687 for those that were
sequenced to be B-Raf600wt.
Absence of B-RafV600E mutations in MCC
To assess a possible role of activated B-Raf in MCC, we
extracted genomic DNA of 49 different paraffin-embedded
MCC tumor samples and performed the real-time PCR assay
described above. For three samples, we did not get any
interpretable data as we could not achieve specific amplifi-
cation, presumably because of bad quality of the genomic
DNA extracts. However, for 46 tumors the DNA was of
sufficient quality and the calculated wt/mut values for all
cases were above 100 (149–32532), indicating that none of
the analyzed MCC carries the B-RafV600E mutation. These
results are in line with a recently published study describing
absence of the B-RafV600E mutation in 15 MCC analyzed
(Worda et al., 2005). Although it is theoretically possible that
MCCs are affected by other B-Raf mutations, this is rather
unlikely, as the vast majority of B-Raf mutations found in
different cancer types represented the T1799A nucleotide
exchange (Davies et al., 2002), and only for non-small-cell
lung cancer the B-RafV600E is not the prevalent B-Raf mutation
(Brose et al., 2002).
Lack of phosphorylated ERK in MCC
Even in the absence of activating B-Raf mutations, a
multitude of other possible alterations in tumors might lead
to signalling through the Raf/MEK/ERK kinase cascade. Those
include (i) the presence of autocrine or paracrine growth
factors, (ii) activating mutations of growth factor receptors or
associated kinases or (iii) mutations of members of the Ras
family (Chen et al., 2001). For example, constitutive
activation of MEK and ERK has been described in uveal
melanoma, although only one sample of the whole series
displayed an activating mutation in one of the Ras family
members, and moreover all samples were negative for
activating B-Raf mutations (Zuidervaart et al., 2005). There-
fore, we scanned the activation status of the Raf/MEK/ERK
cascade by immunohistochemical analysis for the presence
of phosphorylated, that is, activated ERK 1/2 in our series of
MCCs. As activation of the MAP kinase pathway is regularly
seen in melanoma, this tumor served as positive control for
the staining procedure. We received interpretable data from
44 MCC samples; five cases had to be excluded because of a
lack of further tumor material. Staining for phosphorylated
ERK in MCC resulted in a very homogenous picture (Figure 3),
with less than 10% of the cells on the tissue section being
positive for phosphorylated ERK (Table 1). Importantly, no
tumor cells reacted as positive staining was exclusively
present on stromal cells infiltrating or surrounding the tumor
(Figure 3a and b and Table 1). Notably, the lack of ERK
phosphorylation was not because of low expression of ERK
protein as staining for total ERK 1/2 showed that it was
strongly expressed in MCC and staining was even more
prominent in the tumor cells than in infiltrating stromal cells
(Table 1 and Figure 3e). In only two cases, single tumor cells
were positive for phosphorylated ERK (Figure 3c). It should be
further noted, that no differences with respect to ERK
phosphorylation in MCC were evident between primary or
metastatic lesions.
Although there are myriads of papers about the role of the
Ras/Raf/MEK/ERK pathway in transformation and oncogen-
esis, fewer studies have directly addressed the activation of
ERK 1/2 in clinical samples. Among these reports in only one
study, analyzing papillary thyroid carcinomas, an absence of
phosphorylated ERK was demonstrated in tumor cells (Shin
et al., 2004). In contrast, phosphorylated ERK-positive tumor
cells have been described for the breast (Milde-Langosch
et al., 2005), ovarian (Davidson et al., 2003), prostate (Malik
et al., 2002), salivary gland (Handra-Luca et al., 2003), small-
cell lung (Blackhall et al., 2003), and interestingly, non-small-
cell lung cancer (Vicent et al., 2004). Therefore, lack of
activated ERK as detected in MCC is an unusual characteristic
and clearly distinguishes MCC from small-cell lung cancer, to
which it otherwise has many similarities (Poulsen, 2004).
High RKIP expression levels in primary and metastatic MCC
Recently, by means of the two-hybrid screen technology, a
protein was identified that binds to Raf and has the ability to
interrupt interactions between Raf and MEK. Thereby it
prevents the activation of MEK by Raf. Consequently, this
protein was named Raf Kinase Inhibitor Protein (RKIP) (Yeung
et al., 1999). RKIP overexpression interferes with downstream
events such as activation of ERK, induction of AP-1-
dependent reporter genes, and oncogenic transformation
elicited by activated C-Raf (Yeung et al., 1999) or B-Raf
kinase (Park et al., 2005). To answer the question as to
www.jidonline.org 1137
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whether RKIP may be involved in silencing of the MAP kinase
pathway in MCC, we analyzed a representative series of MCC
(n¼20) by immunohistochemistry, and found a strong RKIP
expression in all tumor samples (Table 1). In fact, RKIP
staining clearly distinguished between tumor cells and
surrounding or infiltrating stroma cells, as only a very minor
fraction of stromal cells expressed RKIP (Figure 3g and h). In
80% of the analyzed samples, a homogenous and strong
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Figure 3. Inverse correlation of RKIP and phospho-ERK expression in MCC. Immunohistochemistry of tissue sections of (a–e, g and h) MCC and (f, i) melanoma
to detect the presence of (a–c, f) phosphorylated ERK, (d) Ki-67, (e) total ERK, and (g, h and i) RKIP. (a) and (b) Depict the absence of phosphorylated ERK staining
in MCC with some positive stromal cells in (b). (f) Reactivity for phosphorylated ERK demonstrating typical strong staining found in some melanoma samples.
(c) Very rare presence of phosphorylated ERK-positive tumor cells found in two out of 44 MCC samples (arrows). The high mitotic rate in MCC is indicated by the
high proportion of Ki-67-positive cells. (d) and (e) Demonstrates the presence of total ERK protein in MCC. (g) and (h) Demonstrate the strong RKIP staining of the
tumor cells of MCC tissue sections, whereas (i) is an example of absence of RKIP staining in some of the melanoma samples. Original magnification: (a, g)  10;
(b–d, h) 20; (e, f, i) 40.
Table 1. Expression of ERK 1/2, p-ERK 1/2, and RKIP in Merkel cell carcinoma
Intensity of staining (%) Distribution of positive cells (%) Localization (tissue) (%)
Dim Standard Bright Focal Single cells Broad Stromal cells only Stromal and tumor cells
ERK 20 70 10 20 — 80 — 100
p-ERK 16 77 2 — 100 — 95 5
RKIP 10 75 15 — — 100 — 100
Frequency of positive cells (%) Localization (cells) (%)
o10 10–30 30–60 60–90 490 Nuclear and cytoplasmic Only cytoplasmic
ERK — — 30 40 30 100
p-ERK 100 — — — — 2 98
RKIP — — — 20 80 — 100
The percentages of positive samples in the respective category are given. Forty-four, 20, and 10 slides were analyzed for the presence of p-ERK, RKIP, and
ERK, respectively. The category ‘‘intensity of staining’’ does not describe the absolute level of expression, but rather is a reflection of the variation between
samples.
ERK, extracellular signal-regulated kinase; p-ERK, phosphorylated ERK; RKIP, Raf Kinase Inhibitor Protein.
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expression of RKIP was present. In only four out of 20 tumors,
an absent or weak expression was detectable in a subset of
tumor cells (Table 1); notably, these sections were all derived
from metastatic lesions. In contrast, RKIP expression, like the
presence of phosphorylated ERK, is much more hetero-
geneously observed in melanoma, with some tumor speci-
mens staining completely negative for RKIP (Figure 3i).
Hence, in MCC incoming signals, which might otherwise
activate the MAP kinase pathway, may be terminated by the
presence of high levels of RKIP blocking further signal
transduction to MEK.
Expression of RKIP in melanoma cell lines is low, relative
to primary melanocytes and forced expression of RKIP,
partially reverts the oncogenic action achieved by constitu-
tive B-Raf activation (Park et al., 2005). Furthermore,
immunohistochemical in situ analysis revealed a decline in
RKIP expression during progression of melanocytic lesions
from nevi (completely positive) over primary (focally
negative) to metastatic melanoma (completely negative)
(Schuierer et al., 2004). A similar pattern of RKIP expression
was described for prostate cancer (Fu et al., 2003). These data
together with the notion that RKIP overexpression does not
influence the tumorigenic properties of cancer cells per se,
but rather decreases metastasis formation, led to the
conclusion, that RKIP may be regarded as a suppressor of
metastasis (Fu et al., 2003). As mentioned above, those MCC
samples in which RKIP staining was negative in a consider-
able proportion (10–40%) of the tumor cells (Table 1)
belonged to the group of metastatic MCC, whereas in
primary MCC RKIP was homogeneously and strongly
expressed in all tumor cells. However, this observation is
by no means statistically significant, but the observed trend
towards a reduction of RKIP expression in MCC metastasis
falls into place with its hypothetical role as a metastasis
suppressor. As in some of the samples from metastatic
lesions, a significant proportion of the cells lack detectable
expression of RKIP, at least in these cells absence of
phosphorylated ERK is not attributable to inhibition of MEK
activation by RKIP. Other mechanisms, of which lack of
activating signals from Ras/Raf are the most likely, must be
the reason.
MAP kinase pathway in MCC cell lines
To confirm these in situ observations, we performed Western
blot analyses with total cell lysates of three MCC-derived cell
lines obtained under different culture conditions: (i) con-
fluent, (ii) subconfluent, (iii) after starvation, or (iv) after
starvation and restimulation with fetal calf serum (FCS). This
analysis revealed that in one of the cell lines (UISO), a high
expression of RKIP was associated with a complete absence
of phosphorylated ERK even following FCS stimulation;
notably, ERK 1 and ERK 2 proteins themselves were highly
expressed in this cell line (Figure 4). Hence, this cell line
resembles the situation found in situ. It should be noted,
however, that in two MCC cell lines ERK was phosphory-
lated. This discrepancy may be explained by several
assumptions, for example, that these two cell lines were
derived from a small subpopulation of tumor cells that differs
with respect to MAP kinase pathway activity or that these
differences may have been acquired during the establishment
of the cell lines. In MCC26 cells, ERK phosphorylation was
regulated as it was elevated in cycling cells and strongly
induced in serum-stimulated cells. RKIP expression in
MCC26 cells was low relative to UISO cells. In MCC13
cells, which expressed slightly lower levels of RKIP than
UISO cells, phosphorylated ERK was also detectable; albeit at
much lower levels than those observed in MCC26 cells.
MCC cells proliferate in the absence of active MAP kinase
signalling
Inhibition of signalling through the Ras/Raf/MEK/ERK cascade
was shown to inhibit cell proliferation in several cell systems
(Pages et al., 1993; Frost et al., 1994; DeSilva et al., 1998;
Favata et al., 1998; Kerkhoff et al., 1998). MCC cells,
however, do obviously not depend on this signalling pathway
for proliferation, as demonstrated by the high expression of
the proliferation marker Ki-67 in the majority of MCC cells
(Figure 3d).
Nevertheless, treatment with a farnesyltransferase inhibitor
(FTI) interfering with Ras signal transduction inhibited the
growth of a xenotransplanted MCC cell line in severe
combined immunodeficient mice (Jansen et al., 1999). These
authors, however, did not directly show that Ras signalling
was actively contributing to the growth of this MCC line.
Because in MCC there seems to be no activation of the MAP
kinase pathway, the effect of FTI may be explained either by
inhibition of other Ras-dependent signalling pathways, such
as Akt-signalling, or by FTI affecting other farnesylated
proteins. In this regard it should be noted, that other small
G-proteins of the Rheb family have recently been suggested
as critical targets of FTIs (Basso et al., 2005). Indeed, after
treatment with FTIs K-Ras and N-Ras are alternatively
prenylated by geranylgeranyltransferase-1, and are therefore
Phospho-ERK
1 2 3 4 1 2 3 4 1 2 3 4
MCC13 MCC26 UISO
ERK
RKIP
-Tubulin
Figure 4. RKIP expression and phosphorylation of ERK 1/2 in MCC cell lines.
Western blot analysis of total cell protein lysates from the three MCC cell
lines. Each cell line was cultured under different conditions: as confluent cell
layer in the presence of FCS (1), serum starvation for 6 hours (2), restimulation
with FCS for 20 minutes (3), or as an exponentially growing, semiconfluent
cell monolayer in the presence of FCS (4). The blot was consecutively probed
with antibodies against the indicated proteins in each case with an
intermediate stripping step.
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not very likely to be the key structures for the antioncogenic
effect of FTIs (Sebti and Hamilton, 1997).
Our data would suggest that activation of the MAP kinase
signalling pathway is not involved in the transformation of
Merkel cells. This, however, raises the question which
oncogenic alterations may be relevant for MCC develop-
ment? Mutations of the tumor suppressor p53 and its relative
p73 have been reported to occur with low frequency in MCC
(Van Gele et al., 2000a; Popp et al., 2002b). To this end, we
have sequenced exon 7 of the p53 gene for six of our MCC
samples and detected in one case a missense mutation
leading to an R249S amino-acid exchange (data not shown)
confirming these previous reports. For other major tumor
suppressors such as the Retinoblastoma protein there are
conflicting publications. Although Leonard and Hayard
(1997) described a frequent loss of heterozygosity at
13q14.3 and an absence of Retinoblastoma protein expres-
sion in MCC cell lines and loss of heterozygosity in a region
3p13–p21.1 centered on D3S2 (Leonard et al., 1996), others
did not find any loss of 3p (Popp et al., 2002b). For PTEN
frequent loss of heterozygosity has been reported; however,
the incidence of inactivation of the second allele was very
low (Van Gele et al., 2001). Further candidates for relevant
cancer pathways involved in the oncogenesis of MCC are the
WNT/adenomatosis polyposis coil (APC), the patched
(PTCH)/glioma-associated oncogene (Gli), the hypoxia-indu-
cible factor (HIF1)/vascular endothelial growth factor (VEGF),
and the similar to MAD (SMAD) pathway (Vogelstein and
Kinzler, 2004). However, detailed scrutiny of these pathways
is yet to be undertaken.
CONCLUSION
To date, none of the known tumor suppressors or oncogenes
has been conclusively implicated in the development of
MCC. Our findings that B-Raf is not mutated in MCC and
most notably that the MAP kinase signalling pathway seems
to be completely silenced in both primary and metastatic
lesions of this tumor entity clearly indicate that the Ras/Raf/
MEK/ERK signal transduction pathway is not involved in the
development of MCC. Therefore, alternative signal transduc-
tion pathways seem to be operative in MCC. These have to be
analyzed in order to identify possible molecular targets for
effective therapies of MCC.
MATERIALS AND METHODS
Tumor material and DNA extraction
Paraffin-embedded tumor samples from 49 MCCs (22 primary and
27 metastatic lesions) were obtained by surgical excision. Genomic
DNA was isolated from serial sections using a DNA Isolation Kit
(Qiagen, Hilden, Germany). Tumors were excised for therapeutic
reasons. All tumors have undergone routine histology for diagnosis
as well as additional measures for further prognostic markers.
Informed consent was obtained from all patients before any of these
measures. The retrospective data analysis was conducted accor-
ding to the Declaration of Helsinki Principles and the data
obtained within the study was anonymized and this approach was
approved by the institutional review board (Ethik-Kommission der
Medizinischen Fakulta¨t der Universita¨t Wu¨rzburg; sequential study
number 124/05).
Real-time PCR for the detection of the B-RafV600E mutation
In this assay, the B-RafV600E mutation is detected by comparing the
efficiency of two PCR reactions, one V600E (A1796T) specific and
one specific for the corresponding wt allele.
Following a preamplification PCR for B-Raf exon 15 (10 951C, 20
cycles (3000951C; 3000551C; 2000721C) and 50 721C; primers: FW-15:
50-CATAATGCTTGCTCTGATAGG-30/RW-15: 50-GGCCAAAAATT
TAATCAGTGGA-30) the product was diluted 1/20 into two separate
SybrGreen-PCR reactions (Eurogentec, Seraing, Belgium). In a Gene
Amp 5700 (Applied Biosystems, Darmstadt, Germany), PCR was
performed in 20-ml volumes (20 501C, 100 951C, 43 cycles (3000 951C;
3000 601C; 2000 721C). The oligonucleotide FW-15 served again as
forward primer. The two reverse primers differed only in the last
nucleotide at the 30 end and were either B-Raf 600wt- (50-GAC CCA
CTC CAT CGA GAT TTC A-30) or B-RafV600E-specific (50-GAC CCA
CTC CAT CGA GAT TTC T-30). Parallel to the analysis of samples a
standard curve was generated by amplifying templates of known wt/
mut ratio (Figure 1d) and the equation for the straight line was
determined: DCT¼ a  ln(wt/mut)þ b.
For the samples of unknown genotype, which were processed in
parallel, DCT was determined and wt/mut was estimated using this
equation. For an estimated wt/mut ratio 4100 the samples were
considered to be free of cells carrying a B-RafV600E allele.
It may be of importance that the concentration of genomic DNA
in the standards and the samples is in the same range. However, for
genomic DNA isolated from paraffin-embedded tissue sections, it
was not possible to determine the concentration by UV spectrometry
as the absorbance at 260 nm/absorbance at 280 nm ratio was
generally below 1.5. Therefore, we diluted our standards (genomic
DNA isolated from the cell lines FM3 and FM55M2) in such a way
that the CT values were in the same range as the tumor samples.
Immunohistochemistry
Three micron sections of paraffin-embedded tumors were dried at
561C and then treated two times with xylol for 10 minutes at room
temperature. Subsequently, sections were washed twice with
absolute ethanol and two times with 70% ethanol followed by one
rinse with distilled water. For antigen retrieval, sections were
incubated with citrate buffer (DAKO, Hamburg, Germany), pH 6.0
(phosphorylated ERK and Ki-67), or pH 9.0 (RKIP) for 10 minutes at
901C and rinsed with distilled water. Next, slides were rinsed twice
with phosphate-buffered saline (PBS, DAKO, S3024) and thereafter
incubated with Blocking Solution (DAKO, S2023) for 10 minutes at
room temperature. After two additional washing steps with PBS for
10 minutes at room temperature, the monoclonal antibodies
a-phospho-p44/42 MAP kinase (Thr202/Tyr204) (clone E10; Cell
Signaling, Beverly, CA), a-Ki-67 (clone MIB-1; DAKO) or the
polyclonal antibodies a-RKIP (Upstate, Charlottesville, VA), and
a-p44/42 MAP kinase (Cell Signaling, Beverly, CA) were added to
the sections in PBS, followed by an over night incubation at 41C. After
two two10 minutes washes in PBS, biotinylated multispecies-specific
secondary antibody (DAKO, K5003) was added to the sections for
30 minutes at room temperature. Slides were then washed twice in
PBS/BSA, and bound antibodies were visualized using streptavidin-
horseradish peroxidase (DAKO K5003) and Vector Vip (Vector
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Laboratories, Burlingame,CA) as peroxidase substrate according to
the manufacturer’s guidelines. Finally, the nuclei were stained with
hemalaun.
MCC cell lines and Western blot analysis
The MCC cell lines MCC 13 (Leonard et al., 1995), MCC 26 (Van
Gele et al., 2000b), and UISO (Ronan et al., 1993) were grown in
RPMI 1640 (10% FCS). For protein analysis, cells cultured under the
indicated conditions were lysed on ice in six-well plates using
La¨mmli buffer. Cell lysates were resolved by SDS-PAGE and
transferred to nitrocellulose membranes. Following blocking for
1 hour with PBS containing 0.05% Tween 20 and 5% powdered
skim milk, blots were incubated for 2 hours or overnight with
primary antibody washed three times with PBS with 0.5% Tween 20,
and then incubated with peroxidase-coupled secondary antibody.
Following extensive washing, the bands were detected using a
chemo luminescence detection kit (Roche Diagnostics, Mannheim,
Germany). Besides the antibodies described in the Immunohisto-
chemistry section, a monoclonal antibody recognizing b-tubulin
(Sigma, Taufkirchen, Germany) was used.
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